CD27 is a member of the tumor necrosis factor receptor superfamily. As a co-stimulatory immune checkpoint molecule, it is the target of an anti-cancer drug in clinical trials. CD27 is expressed on both naive and activated effector T cells as well as NK cells and activated B cells. CD27 is a member of the TNF-receptor superfamily and is required for generation and long-term maintenance of T cell immunity. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis. When CD27 binds CD70, a signaling cascade leads to the differentiation and clonal expansion of T cells. The cascade also results in improved survival and memory of cytotoxic T cells and increased production of certain cytokines. CD27-binding protein (SIVA), a proapoptotic protein, can bind to this receptor and is thought to play an important role in the apoptosis induced by this receptor.